00867 CMS
- 7.200
- +0.130+1.84%
CMS News
China Medical System Holdings (HKG:867) Has A Pretty Healthy Balance Sheet
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Haitong International: Free circuit with long slopes and heavy snow, domestic market space is expected to open up
The Zhitong Finance App learned that Haitong International released a research report saying that compared with innovative domestic drugs to replace relatively mature oncology drugs, self-exempt drugs also have the advantage of a large market size (suitable for the domestic pricing environment for new drugs). The differences are that patients are widely distributed (channel coverage is required), are more chronic diseases, and there is competition for traditional drugs (requiring fast efficacy and high accessibility). Combined with the current market financing environment, although the self-defense target layout is still crowded, companies with good cash flow will be more likely to obtain excess profits. It is recommended to pay attention to Hengrui Pharmaceutical (600276.SH), Kangzhe Pharmaceutical (00867), Sansheng Guojian (688)
Kangzhe Pharmaceutical (00867.HK) spent HK$7.3872 million to buy back 1.05 million shares on April 24
Gelonghui, April 24 | Kangzhe Pharmaceutical (00867.HK) announced that it spent HK$7.3872 million to repurchase 1.05 million shares on April 24.
China Medical System: New Drug Application of Desidustat Tablets Accepted in China
SHENZHEN, CHINA, April 23, 2024 (GLOBE NEWSWIRE) -- Desidustat Tablets are novel, oral HIF-PHI for treating anaemia in non-dialysis adult chronic kidney disease patients. The Product is administrate
Kangzhe Pharmaceutical (00867.HK): The application for permission to market dexidolastat tablets in China has been accepted
Gelonghui, April 23 | Kangzhe Pharmaceutical (00867.HK) announced that the new drug marketing license application (NDA) for desidustat tablets (former name: dudostat tablets) was accepted by the China National Drug Administration (NMPA) on April 22, 2024. The product is an innovative oral hypoxia-inducible factor-proline hydroxylase inhibitor (HIF-PHI), intended for the treatment of anemia in non-dialyzed adult patients with chronic kidney disease (CKD). CKD patients gradually lose kidney function and eventually develop kidney failure. Healthy kidneys naturally secrete erythropoietin (EPO), which stimulates
Kangzhe Pharmaceutical (00867.HK) spent HK$7.423,800 to buy back 1.06 million shares on April 17
Gelonghui, April 17 | Kangzhe Pharmaceutical (00867.HK) announced that it spent HK$7.423,800 to buy back 1.06 million shares on April 17.
康哲藥業：股東週年大會通告
康哲藥業：2023年度報告
China Medical System Registers New Vitiligo Drug in Macau
China Medical System Holdings (HKG:0867) said its Vitiligo drug was registered by Macau's Pharmaceutical Administration Bureau (ISAF), according to a Tuesday filing on the Hong Kong bourse. Ruxolitini
NeuroX, American TelePhysicians' Brain Health Division, Selected as Participant in CMS GUIDE Program
JACKSONVILLE, Fla., April 16, 2024 /PRNewswire/ -- NeuroX, a pioneering healthcare company revolutionizing brain health, in conjunction with its affiliated physician network, ATP Partners, has been c
Kangzhe Pharmaceutical (00867.HK) spent HK$7.44 million to buy back 1.05 million shares on April 15
Gelonghui, April 15 | Kangzhe Pharmaceutical (00867.HK) announced that it spent 7.44 million HK$7.44 million to repurchase 1.05 million shares on April 15.
Kangzhe Pharmaceutical (00867.HK) spent HK$7.64 million to buy back 1.05 million shares on April 12
Gelonghui, April 12 | Kangzhe Pharmaceutical (00867.HK) announced that it spent 7.64 million HK$7.64 million to repurchase 1.05 million shares on April 12.
Kangzhe Pharmaceutical spent HK$7.993 million to buy back 1.1 million shares on April 11
Kangzhe Pharmaceutical (00867) announced that on April 11, 2024, the company spent HK$7.993 million to repurchase 1.1 million shares at a repurchase price of HK$7.16-7.34 per share.
Kangzhe Pharmaceutical (00867.HK) spent HK$7.993 million to buy back 1.1 million shares on April 11
Gelonghui, April 11 | Kangzhe Pharmaceutical (00867.HK) announced that it spent HK$7.993 million to repurchase 1.1 million shares on April 11.
Kangzhe Pharmaceutical (00867) spent HK$7.674 million to buy back 1.03 million shares on April 10
Kangzhe Pharmaceutical (00867) announced that the company spent HK$7.674 million on April 10, 2024...
Kangzhe Pharmaceutical (00867) spent HK$7.636,600 to buy back 1 million shares on April 9
Kangzhe Pharmaceutical (00867) announced that on April 9, 2024, the company spent HK$7.636,600 to return...
Kangzhe Pharmaceutical (00867) spent about HK$11.754 million to buy back 1.55 million shares on April 8
According to the Zhitong Finance App, Kangzhe Pharmaceutical (00867) announced that on April 8, 2024, it spent approximately HK$11.754 million to repurchase 1.55 million shares.
Kangzhe Pharmaceutical (00867.HK) spent HK$11.08 million to buy back 1.47 million shares on April 3
Gelonghui, April 3 | Kangzhe Pharmaceutical (00867.HK) announced that it spent HK$11.08 million to buy back 1.47 million shares on April 3.
CMS' Medicare Advantage Rate Sends Humana -13%, UnitedHealth -6%
Humana's stock tumbled to a four-year low and UnitedHealth's stock led the Dow's decliners toward a 9-month low.
Kangzhe Pharmaceutical (00867.HK) spent HK$15.642 million to buy back 2.1 million shares on April 2
Gelonghui, April 2 | Kangzhe Pharmaceutical (00867.HK) announced that it spent HK$15.642 million to repurchase 2.1 million shares on April 2.
Analysis
Price Target
No Data
